NLF2 Inhibitors

NLF2 Inhibitors principally target various cell signaling pathways that may be associated with the functions or interactions of NLF2, even though direct inhibition is not confirmed.

Rapamycin, known to inhibit the mTOR pathway, is a classic representative of a compound that affects a plethora of cellular processes, including those that NLF2 might be involved in. Similarly, LY294002 and Wortmannin are PI3K inhibitors. PI3K is an upstream modulator in many signaling pathways, connecting to NLF2 functions. Additionally, MEK and ERK pathways, inhibited by U0126 and PD98059 respectively, play significant roles in cell growth, differentiation, and survival. Their broad reach can indirectly touch upon NLF2-associated processes. In the realm of stress and inflammatory responses, the JNK and p38 MAPK pathways, inhibited by SP600125 and SB203580 respectively, are of note. NLF2, if related to these pathways, might be influenced by these inhibitors. Similarly, BAY 11-7082 and the generic IκB kinase inhibitor act on the NF-κB pathway, a key regulator of immune response, cell growth, and survival. Staurosporine's broad-spectrum kinase inhibition can have wide-ranging effects on cell signaling. PP2, as a Src family kinase inhibitor, touches on cell growth and differentiation pathways that NLF2 may be a part of. Finally, Alisertib, an Aurora kinase inhibitor, primarily affects cell cycle and proliferation processes.